These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2521422)

  • 21. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltration.
    Sebert JL; Fournier A; Leflon P; Fohrer P; de Frémont JF; Morinière P; Galy C; Marie A; Demontis R; Boudailliez B
    Nephron; 1986; 42(1):34-40. PubMed ID: 3941748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients.
    Faugere MC; Malluche HH
    Kidney Int; 1986 Nov; 30(5):717-22. PubMed ID: 2431192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients.
    London GM; De Vernejoul MC; Fabiani F; Marchais SJ; Guerin AP; Metivier F; London AM; Llach F
    Kidney Int; 1987 Dec; 32(6):900-7. PubMed ID: 2963169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.
    Kausz AT; Antonsen JE; Hercz G; Pei Y; Weiss NS; Emerson S; Sherrard DJ
    Am J Kidney Dis; 1999 Oct; 34(4):688-93. PubMed ID: 10516350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between hair, serum and bone aluminium in hemodialyzed patients.
    Chappuis P; de Vernejoul MC; Paolaggi F; Rousselet F
    Clin Chim Acta; 1989 Feb; 179(3):271-8. PubMed ID: 2714000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parathyroid glands in chronic aluminum intoxication.
    Cournot-Witmer G; Plachot JJ
    Ultrastruct Pathol; 1990; 14(3):211-9. PubMed ID: 2356587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients?
    Friga V; Linos A; Linos DA
    Nephron; 1997; 75(1):48-53. PubMed ID: 9031270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Initial evaluation of aluminum concentrations in patients with nephropathy and undergoing hemodialysis at the Miguel Pérez Carreño Hospital and the University Hospital of Caracas (Venezuela)].
    Parra OE; Navarro JA; de Ardila M; Weissinger J; Domínguez J; Gutiérrez LE; Carlini R; Mendoza JA; Salgado OJ; Romero RA
    Invest Clin; 1989; 30(4):193-203. PubMed ID: 2488708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
    Tarng DC; Huang TP
    Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.
    Molitoris BA; Alfrey AC; Alfrey PS; Miller NL
    Kidney Int; 1988 Jul; 34(1):98-101. PubMed ID: 3172641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of serum aluminum values with tissue aluminum concentration.
    De Broe ME; Van de Vyver FL; Bekaert AB; D'Haese P; Paulus GJ; Visser WJ; Van Grieken R; de Wolff FA; Verbueken AH
    Contrib Nephrol; 1984; 38():37-46. PubMed ID: 6713899
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of hemodialysis on left ventricular performance. Analysis of echocardiographic subsets.
    Madsen BR; Alpert MA; Whitting RB; Van Stone J; Ahmad M; Kelly DL
    Am J Nephrol; 1984; 4(2):86-91. PubMed ID: 6232848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone aluminum and histomorphometric features of renal osteodystrophy.
    Hodsman AB; Sherrard DJ; Alfrey AC; Ott S; Brickman AS; Miller NL; Maloney NA; Coburn JW
    J Clin Endocrinol Metab; 1982 Mar; 54(3):539-46. PubMed ID: 7056841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure.
    Mitsnefes MM; Kimball TR; Witt SA; Glascock BJ; Khoury PR; Daniels SR
    Circulation; 2003 Feb; 107(6):864-8. PubMed ID: 12591757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trend evaluation of aluminium in uraemic patients on chronic hemodialysis.
    Di Iorio BR; Scarpino L; Bruno A; Confessore A; Gaudiano G; Altieri C; Smilari F; Papaleo D; Cosentino G; Terracciano V
    Nephron; 1995; 71(4):471-2. PubMed ID: 8587634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.